The radiopharmaceutical research group at MURR focuses on development of radioisotopes for use in detecting and treating cancer and other chronic human diseases. 

Through alliances with University of Missouri faculty, government laboratories and private industry, MURR scientists have successfully developed three FDA approved radiopharmaceutical agents: Ceretec™, the first brain imaging agent; TheraSphere®, a treatment for liver cancer; and Quadramet®, an agent designed to relieve the excruciating pain associated with metastatic bone cancer.

Major attention is being given currently to developing carrier-free radiolanthanides and targeting agents that can be used to provide a range of treatment options for various forms of cancer.